Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-118958
Filing Date
2024-10-30
Accepted
2024-10-30 16:05:26
Documents
68
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q dawn-20240930.htm   iXBRL 10-Q 2776659
2 EX-10.1 dawn-ex10_1.htm EX-10.1 828855
3 EX-31.1 dawn-ex31_1.htm EX-31.1 13748
4 EX-31.2 dawn-ex31_2.htm EX-31.2 13570
5 EX-32.1 dawn-ex32_1.htm EX-32.1 7901
6 EX-32.2 dawn-ex32_2.htm EX-32.2 8802
7 GRAPHIC img13569215_0.jpg GRAPHIC 116042
  Complete submission text file 0000950170-24-118958.txt   11298004

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT dawn-20240930.xsd EX-101.SCH 1652510
70 EXTRACTED XBRL INSTANCE DOCUMENT dawn-20240930_htm.xml XML 1523261
Mailing Address 2000 SIERRA POINT PARKWAY, SUITE 501 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY, SUITE 501 BRISBANE CA 94005 650 484-0899
Day One Biopharmaceuticals, Inc. (Filer) CIK: 0001845337 (see all company filings)

EIN.: 832415215 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40431 | Film No.: 241410263
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)